Based on Your Reading:
Get a Mesothelioma Treatment Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
CAR T-Cell Therapy for Mesothelioma
Table Of Contents
CAR T-cell therapy is an emerging immunotherapy treatment where a patient’s T cells are changed in a laboratory to better recognize and attack cancer cells. It is effective against advanced blood cancers, but questions remain if it will ever be a viable option for solid tumors such as mesothelioma.
Written by Karen Selby, RN | Medically Reviewed By Dr. Andrea Wolf | Edited By Walter Pacheco | Last Update: August 6, 2024
"Most helpful, steered us in the right direction for treatment. Great source of information and support, the Center followed through on every one of our requests...." see more
Elaine C.
Mesothelioma Patient
"Because of their guidance, I was able to navigate getting my mother into MD Anderson when her case got put aside by mistake in all the COVID-19 craziness. Vanes...." see more
Deanna B.
Daughter of a Mesothelioma Patient
"Hearing the news about my mother's diagnosis was heartbreaking. I felt lost, I didn't know how I could help or where to seek the best medical care. I started re...." see more
Danielle W.
Daughter of a Mesothelioma Patient
"My son Carlos was diagnosed with this terrible and unknown disease a few months ago. Thank God we found The Mesothelioma Center along the way, and Vanessa Blanc...." see more
Martha M.
Mother of a Mesothelioma Patient
"Extremely communicative and helped my dad get an appointment with one of the top centers in Philadelphia. I'm so grateful for this center. They assisted with in...." see more
Sunni H.
Loved One of a Mesothelioma Patient
"Danielle DiPietro was an invaluable resource for me. Her suggestions and recommendations guided us towards stellar practitioners in our area. Without her advoca...." see more
Deborah C.
Spouse of a Mesothelioma Patient
"I was very grateful and appreciative of Dr. Smart from The Mesothelioma Center. She was very helpful to my husband and me. She educated and walked us through th...." see more
Kimberlin C.
Spouse of a Mesothelioma Patient
"In January of 2016, my husband was diagnosed with peritoneal mesothelioma. Our first reaction was: what is this and what can we do? He was diagnosed by an oncol...." see more
Gloria R.
Spouse of a Mesothelioma Patient
Written by Karen Selby, RN | Medically Reviewed By Dr. Andrea Wolf | Edited By Walter Pacheco | Last Update: August 6, 2024
What is CAR T-Cell Therapy?
CAR T-cell therapy is the most common and heavily studied type of adoptive cell transfer (ACT). This promising immunotherapy approach collects and uses a patient’s own immune cells to treat cancer.
This treatment uses white blood cells called T cells to help protect the body from infection and disease. Some cancer cells have special proteins on their surface that can make it hard for the T cells to recognize them, so they don’t get attacked.
CAR T-cell therapy gets around this deception and boosts the immune response in two ways:
- Special cells in our bodies called T cells can be modified to have special receptors on them. They’re called chimeric antigen receptors, or CARs. They allow T cells to recognize and latch on to specific proteins (antigens) on cancer cells and initiate an attack.
- Millions of these engineered CAR T cells are grown in a laboratory and then given to the patient by infusion.
In 2017, the U.S. Food and Drug Administration approved CAR T-cell therapies for children with acute lymphoblastic leukemia and adults with advanced lymphomas. Clinical trials testing CAR T-cell therapy on mesothelioma and other solid tumor cancers are underway.
How Does CAR T-Cell Therapy Work?
CAR T-cell therapy works by increasing the number of T cells capable of recognizing cancer cells. This boosts the immune system’s offense to fight cancer.
The engineered CAR T cells are like a living drug. The chimeric antigen receptors added to the T cells are synthetic molecules that don’t exist naturally. This allows the modified T cells to target cancer cells and overcome the cancer’s defense.
Process of CAR T-Cell Therapy
- Blood is drawn from the patient to get T cells. The blood flows through a tube to an apheresis machine that removes T cells and other white blood cells. The rest of the blood is returned to the patient.
- T cells are sent to a lab. Using a disarmed virus, the CARs are added to the extracted T cells.
- Engineered CAR T cells are multiplied until there are millions. They are then frozen and sent to the hospital or medical center where the patient will be treated.
- The patient typically undergoes a chemotherapy regimen to make space for the large number of modified T cells.
- CAR T cells are put into the patient’s bloodstream and continue to multiply.
- The added CARs are attracted to antigens on the surface of cancer cells, allowing the T cells to bind to cancer cells and kill them.
CAR T cells may remain in the body months after the infusion to prevent cancer recurrence.
Possible Side Effects from CAR T-Cell Therapy
The most common side effect of CAR T-cell therapy is cytokine release syndrome (CRS).
Cytokines are chemical messengers that help T cells carry out their functions. These are produced when the CAR T cells multiply in the body.
The rapid release of cytokines can cause CRS. Symptoms of CRS range from mild flu-like symptoms (fever, fatigue, chills) to more severe symptoms such as dangerously low blood pressure, rapid heart rate, internal bleeding and heart failure.
CRS can be difficult to measure and manage because it means the CAR T-cell therapy is working. This is called an on-target effect. Patients with extensive disease typically experience more severe CRS symptoms.
CRS can be fatal, but most symptoms can be managed with standard supportive therapies such as tocilizumab.
Find a Mesothelioma Cancer Center
Access top mesothelioma cancer centers that have experience treating this rare disease.
Get Help NowCAR T-Cell Therapy Research for Mesothelioma
Research for CAR T-cell therapies is largely focused on blood cancers, but recent studies are evaluating this treatment for patients with solid tumors, including malignant mesothelioma.
The biggest challenge facing researchers is finding suitable antigens to target on solid tumors.
Fortunately for mesothelioma patients, one of the antigens investigators are targeting in clinical trials is mesothelin, a protein overexpressed in most mesotheliomas.
A 2021 study of anti-mesothelin CAR T-cell therapy reported stable disease in 11 out of 15 patients 28 days after treatment. The study noted that five of those patients developed disease progression at a later point.
A phase I/II trial at the National Cancer Institute in Bethesda, Maryland, is evaluating the safety of a CAR T-cell therapy against mesothelin in patients with cancer that cannot be removed by surgery.
“The purpose of this study is to determine a safe number of these cells to infuse and to see if these tumor-fighting cells (anti-mesothelin cells) cause metastatic cancer tumors to shrink,” the objective of the clinical trial reads.
Other potential targets being studied for mesothelioma include:
- Vascular endothelial growth factor receptor 2 (VEGFR2) CAR
- Pan-ErbB “T4” CAR
- 5T4 CAR
- Chondroitin sulfate proteoglycan CARs
However, early reports from the trial have not shown the same success CAR T-cell therapy has had with blood cancer. The anti-mesothelin trial is expected to run through 2029.
Researchers at the University of Pennsylvania Perelman School of Medicine authored a 2017 study listing potential targets for CAR T-cell therapy for malignant pleural mesothelioma (MPM) and strategies for using the treatment with other forms of immunotherapy.
In addition to mesothelin, the study identifies fibroblast activation protein (FAP) as a potential target. FAP is overexpressed in all three subtypes of MPM.
“The results of these trials will be used to iteratively improve the next series of trials, eventually leading, it is hoped, to adoptive T cell transfer as an important part of the MPM therapeutic armamentarium,” the study concluded.
This Page Contains 5 Cited Articles
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
- Castelletti, L. et al. (2021, February 15). Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. Retrieved from https://link.springer.com/article/10.1186/s40364-021-00264-1
- National Cancer Institute. (2017, December 14). CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers. Retrieved from https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
- National Cancer Institute. (n.d.). CAR T-cell therapy. Retrieved from https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy
- Leukemia & Lymphoma Society. (n.d.). Chimeric Antigen Receptor (CAR) T-Cell Therapy. Retrieved from http://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy
- Klampasta, A. et al. (2017, September). Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615330/#sec7-cancers-09-00115title
Get Your Free Mesothelioma Treatment Guide
Mesothelioma & Immunotherapy Webinar
Immunotherapy & Mesothelioma Clinical Trials
